
Fast track designation has been granted by the FDA to eryaspase for the treatment of patients with acute lymphocytic leukemia who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase.

Fast track designation has been granted by the FDA to eryaspase for the treatment of patients with acute lymphocytic leukemia who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase.

Marcin Kortylewski, PhD, discusses the need for additional strategies for the treatment of acute myeloid leukemia.

A warning from the FDA highlights that an increased rate of death has been observed in patients with multiple myeloma who are undergoing treatment with the FDA-approved agent melphalan flufenamide in combination with dexamethasone in the phase 2 OCEAN clinical trial.

Selinexor has been administered in combination with ruxolitinib to the first patient with treatment-naïve myelofibrosis as part of a phase 1/2 clinical trial.

Camidanlumab tesirine is a potential treatment option for relapsed or refractory lymphoma with a tolerable safety profile, particularly in patients with classical Hodgkin lymphoma.

Haris Ali, MD, discusses the use of ruxolitinib as peri-transplant treatment for patients with myelofibrosis.

In an interview with Targeted Oncology, Bobbie J. Rimel, MD, discussed the phase 2 NRG-GY012 results and the next step for cediranib plus olaparib as treatment of recurrent or metastatic endometrial cancer.

Wearable medical devices, whether they be smart watches or wearable at-home infusion devices or pumps, are playing a more prominent role in cancer care.

Between 2014 and 2018, there was an overall decline in cancer deaths in men, women, and children of all racial and ethnic groups in the United States.

The first patient with an advanced solid tumor has been dosed with the first-in-class anti-PVRIG antibody, COM701, in combination with nivolumab and the anti-TIGIT antibody, BMS-986207, in a phase 1/2 clinical trial.

In an interview with Targeted Oncology, Guiseppe Curigliano, MD, an associate professor of Medical Oncology at the University of Milano and the head of the Division of Early Drug Development at the European Institute of Oncology, discussed the HER2Climb study and the impact of tucatinib in HER2-positive breast cancer care.

The treatment plan for a woman with multiple myeloma, including which imaging to order, choice of second-line therapy, managing comorbidities, and backbone therapy choice, was discussed during a recent Cased-Base Roundtable event led by Clifton C. Mo, MD.

In an interview with Targeted Oncology, Ainhoa Madariaga, MD, explained the similarities between the primary and exploratory analyses of adavosertib and gemcitabine in patients with ovarian cancer as it relates to toxicity.

DAY101, an investigational, oral, brain-penetrant, and highly selective type II pan-RAF kinase inhibitor for the treatment of rare, pediatric low-grade glioma, was granted a rare pediatric disease designation by the FDA.

Asparaginase has been added to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for the treatment of adult and pediatric patients with acute lymphoblastic leukemia.

In an interview with Targeted Oncology, Melissa M. Hardesty, MD, explained the state of gynecologic oncology treatment for rural patients in Alaska and how research is finding answers for improving clinical outcomes.

The FDA has granted approval to pembrolizumab for the treatment of patients with high-risk early-stage triple-negative breast cancer in combination with chemotherapy as neoadjuvant treatment and then continued as a single agent as adjuvant treatment after surgery.

Samantha E. Greenberg, MS, MPH, CGC, discusses if the changes to the National Comprehensive Cancer Network’s Clinical Practice Guidelines for Prostate Cancer. NCCN has expanded germline testing in metastatic prostate cancer to all patients with high-risk, very high-risk, or regional prostate cancer.

Treatment with mogamulizumab-kpkc in adult patients with cutaneous T-cell lymphoma, including mycosis fungoides or Sézary syndrome, demonstrated better outcomes in those who had higher levels of blood involvement at baseline assessment, according to results of a post-hoc analysis for the MAVORIC trial.

The FDA has granted an orphan drug designation to the anticancer drug paclitaxel-hyaluronic acid for the treatment of malignant mesothelioma.

The indication for nivolumab as a single agent for the treatment of hepatocellular carcinoma in patients previously treated with sorafenib has been withdrawn from the US market.

The FDA issued a complete response letter to Incyte Corporation in response to the Biologics License Application for the PD-L1 inhibitor, retifanlimab for the treatment of adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal who have progressed on, or who are intolerant of, platinum-based chemotherapy.

The FDA has granted priority review to the New Drug Application for nab-sirolimus for consideration as a treatment for patients with advanced malignant perivascular epithelioid cell tumors.

Travis Sims, MD, MPH, discusses the impact of homologous recombination deficiency status of clinical and survival outcomes in patients with advanced-stage ovarian cancer.

In an interview, Robert J. Motzer, MD, explained how further results of the CLEAR trial, including health-related QOL data, suggest the benefit of pembrolizumab and lenvatinib in patients with advanced RCC.

Sintilimab in combination with the bevacizumab biosimilar, IBI305, is associated with a significant overall survival and progression-free survival benefit over sorafenib in the first-line setting for the treatment of Chinese patients with unresectable, hepatitis B virus-associated hepatocellular carcinoma.

Eprenetapop combined with azacitidine has shown positive efficacy as post-transplant maintenance therapy for patients with TP53-mutant myelodysplastic syndrome and acute myeloid leukemia treated in a phase 2 study.

Nathan Pennell, MD, PhD, discusses the cost-effectiveness of adjuvant osimertinib in resected EGFR-mutant non-small cell lung cancer.

A phase 3 study has been initiated in order to evaluate the efficacy of the oral MDM2 inhibitor milademetan for the treatment of de-differentiated liposarcoma.

The overall survival benefit of immunotherapy combinations compared with sunitinib for the treatment of patients with metastatic renal cell carcinoma who have favorable risk may differ from those who have intermediate or poor risk, according to a pooled analysis of frontline combination therapy conducted by the FDA.